Results 31 to 40 of about 26,042 (243)

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi, A Gothot, A Strife, A Wilson, AHG Hamilton, AR Oller, Bayard Clarkson, BJ Druker, C Cobaleda, C Roche-Lestienne, CH Jamieson, Christophe Fraser, CL Sawyers, D Dingli, E Passegue, F Arai, F Michor, F Michor, F Michor, Franziska Michor, GB Bradford, H Glimm, HG Jorgensen, I Roeder, J Cashman, J Cortes, Jasmine Foo, JC Wang, JD Rowley, JF Apperley, KJ Hope, KW Orford, L Ponchio, M Holtz, Mark W. Drummond, ME Gorre, MJ Mauro, MW Drummond, N Uchida, NL Komarova, NL Komarova, NP Shah, P Rousselot, PS Kim, S Branford, S Branford, S Merante, SM Graham, T Higashi, T Holyoake, T Lapidot, T Reya, Tessa Holyoake, TL Holyoake, W Ghanima, WR Bruce, Y Wang   +56 more
core   +4 more sources

Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor [PDF]

, 2019
The management of advanced gastrointestinal stromal tumors (GISTs) has evolved in the modern era due to the discovery of c-kit mutations and the development of tyrosine kinase inhibitors (TKIs).
Feizpour, Cyrus, Kays, Joshua K., Kim, Bradford J., Koniaris, Leonidas G., Milgrom, Daniel P.   +4 more
core   +1 more source

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Asian Pacific Journal of Tropical Biomedicine, 2016
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz, Marjan Khosravani, Sepideh Mohammadi, Hassan Noorbazargan, Amir Mirzaie, Davoud Nouri Inanlou, Mojgan Dalirsaber Jalali, Hamidreza Jouzaghkar, Fahimeh Baghbani-Arani, Behta Keshavarz-Pakseresht   +9 more
doaj   +1 more source

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Turkish Journal of Hematology, 2015
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi   +7 more
doaj   +1 more source

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Jurnal Penyakit Dalam Indonesia, 2020
Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi, Ary Harryanto Reksodiputro   +1 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

OncoImmunology, 2018
Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias   +12 more
doaj   +1 more source

Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report

Veterinární Medicína, 2019
A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem.
Joong Hyun Song, Tae Sung Hwang, Hee Chun Lee, Do Hyeon Yu, Byung Joon Seung, Jung Hyang Sur, Dong In Jung   +6 more
doaj   +1 more source